Amgen Aranesp, Anakinra Could Lead 2001 Biologics Approvals
Executive Summary
Amgen anticipates approval for two new biologics in 2001, the red blood cell stimulating factor Aranesp and the interleukin-1 receptor antagonist anakinra.
You may also be interested in...
Biologics Approval Time Drops To 19 Months In 2001
The average approval time for a new therapeutic/ vaccine biologic application in 2001 was 19 months, a five-month improvement over 2000
Biologics Approval Time Drops To 19 Months In 2001
The average approval time for a new therapeutic/ vaccine biologic application in 2001 was 19 months, a five-month improvement over 2000
Lilly Oritavancin Antibacterial Agent NDA Submission Targeted For 2003
Lilly expects to file an NDA for the antibacterial glycopeptide oritavancin by 2003, Senior VP-Pharmaceutical Products John Lechleiter, PhD, told the J.P. Morgan H&Q Healthcare Conference in San Francisco Jan. 8.